Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Path to Sarepta Therapeutic (SRPT) Eteplirsen Filing Taking Shape - Needham & Company
May 8, 2014 12:35 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q1 results and more details on the path to the eteplirsen filing.
Messer commented, "As we learned last month, Sarepta plans to file the NDA for eteplirsen in Duchenne's muscular dystrophy (DMD) by YE:14 based on recent discussion with the FDA. The company is moving forward on this groundbreaking event and is also preparing to start 3 additional eteplirsen studies as well as a controlled study for 2 additional exon skipping drug for DMD this... More
